Most of the compounds have physiologically active properties, and their biological properties are often attributed to the heteroatoms contained in their molecules, and most of these heteroatoms also appear in cyclic structures. A Journal, Article, European Journal of Medicinal Chemistry called Development of peptide epoxyketones as selective immunoproteasome inhibitors, Author is Li, Xuemei; Hong, Duidui; Zhang, Mengmeng; Xu, Lei; Zhou, Yubo; Li, Jia; Liu, Tao, which mentions a compound: 120099-61-8, SMILESS is CO[C@@H]1CNCC1, Molecular C5H11NO, Safety of (S)-3-Methoxypyrrolidine.
A series of epoxyketone analogs with varying N-caps and P3-configurations were designed, synthesized and evaluated. We found that D-Ala in P3 was crucial for β5i selectivity over β5c. Notably, compounds (I) (R1 = II) (β5i IC50 = 26.0 nM, 25-fold selectivity) and I (r1 = III) (β5i IC50 = 25.1 nM, 24-fold selectivity) with the D-configuration at P3 were the most selective inhibitors. Although I (R1 = II and III) showed only moderate anti-proliferative activity against RPMI-8226 and MM.1S cell lines, based on our experiments, it indicates that the inhibition of β5i alone is not sufficient to exert anticancer effects and may rely on the complementary inhibition of β1i, β5c and β5i. These data further increase our understanding of immunoproteasome inhibitors in hematol. malignancies.
This literature about this compound(120099-61-8)Safety of (S)-3-Methoxypyrrolidinehas given us a lot of inspiration, and I hope that the research on this compound((S)-3-Methoxypyrrolidine) can be further advanced. Maybe we can get more compounds in a similar way.
Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia